Results 151 to 160 of about 7,633 (200)
Some of the next articles are maybe not open access.

The Association of Mesalamine With Kidney Disease

Advances in Chronic Kidney Disease, 2020
The package inserts for products containing 5-aminosalicylic acid, or mesalamine, include the following language regarding the risk of adverse kidney effects: "renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and rarely renal failure, has been reported in patients given products such as mesalamine ...
Avinash, Adiga, David S, Goldfarb
openaire   +2 more sources

Mesalamine in Ulcerative Colitis

DICP, 1991
Sulfasalazine has been used for many years in the management of ulcerative colitis. As many as 20 percent of patients treated with it experience intolerable adverse effects usually attributed to its sulfapyridine component. The other active component is 5-aminosalicylic acid (5-ASA); the only 5-ASA enema preparation currently available in the U.S.
J M, Fitzgerald, T D, Marsh
openaire   +2 more sources

Mesalamine-Induced Granulomatous Hepatitis

American Journal of Gastroenterology, 1999
A 42-yr-old man with ulcerative colitis was admitted for investigation of prolonged fever associated with cholestatic liver tests. Endoscopic retrograde cholangiopancreatography demonstrated a normal biliary tree, and liver biopsy showed granulomata.
M, Braun   +4 more
openaire   +2 more sources

MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations

Digestive and Liver Disease
Medical therapy is the cornerstone of ulcerative colitis (UC) management and aims to induce and maintain remission. In case of mild-to-moderate UC, mesalamine (5-ASA) is the first-line option. 5-ASA requires local release at the level of the inflamed mucosa to exert its therapeutic action.
Ferdinando, D'Amico   +3 more
openaire   +2 more sources

MMX mesalamine.

Reviews in gastroenterological disorders, 2006
Most current drug delivery systems in the treatment of ulcerative colitis and Crohn's disease release the active drug at the least effective location for treatment. The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral
openaire   +1 more source

Mesalamine lung toxicity.

Connecticut medicine, 2010
Lung toxicity associated with 5-aminosalicylate (5-ASA) agents is very rare. We report the case of a 48-year-old man with ulcerative colitis who developed progressive shortness of breath while taking oral mesalamine. Chest imaging revealed a ground glass appearance in patchy areas distributed throughout the lung. He had a restrictive ventilatory defect
Neha, Jain   +2 more
openaire   +1 more source

Multicenter Survey on Mesalamine Intolerance in Patients With Ulcerative Colitis

Journal of Gastroenterology and Hepatology (Australia), 2021
Akiko Fujiwara, Jun Kato, Reiji Higashi
exaly  

Genetic Background of Mesalamine-Induced Fever and Diarrhea in Japanese Patients With Inflammatory Bowel Disease.

Inflammatory Bowel Diseases, 2022
Atsushi Masamune   +2 more
exaly  

Mesalamine

2001
A DASH, H BNTTAIN
openaire   +2 more sources

Home - About - Disclaimer - Privacy